Daisuke Nakata

Discovery of 1-{4-[1-(2,6-Difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3- <i>d</i> ]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a Potent, Orally Active, Non-Peptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor

Kazuhiro Miwa, Takenori Hitaka, Takashi Imada et al. · Journal of Medicinal Chemistry · 2011 · 98 citations · Full text

Enhancement of oral bioavailability of coenzyme Q10 by complexation with γ-cyclodextrin in healthy adults

Keiji Terao, Daisuke Nakata, Hiroshi Fukumi et al. · Nutrition Research · 2006 · 91 citations

Pharmaceutical Science, Oral Bioavailability, Coenzyme Q10 +6

Anti‐tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC‐dependent vulnerability

Kenichi Iwai, Masahiro Yaguchi, Kazuho Nishimura et al. · EMBO Molecular Medicine · 2018 · 89 citations · Full text

Retinal Neuronal Death Induced by Intraocular Administration of a Nitric Oxide Donor and Its Rescue by Neurotrophic Factors in Rats

Kazue Takahata, Hiroshi Katsuki, Toshiaki Kume et al. · Investigative Ophthalmology & Visual Science · 2003 · 71 citations

Suppression of the hypothalamic–pituitary–gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: Studies in human GnRH receptor knock-in mice

Daisuke Nakata, Tsuneo Masaki, Akira Tanaka et al. · European Journal of Pharmacology · 2013 · 64 citations

Endocrine Mechanism, Medicine, Hormonal Receptor +11